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Introduction 
 
The WT1 gene was originally isolated from Wilms tumor, a childhood 
kidney malignancy. It encodes a zinc finger protein which acts as a 
transcription factor that regulates gene expression. Several types of embryonic 
cells initially express WT1, in adults however, the gene is only expressed in 
select tissue types, if it is expressed at all. Originally it had been known as a 
tumor suppressor gene until its role was revealed as an oncogenic factor in 
malignancies such as breast, lung, colon, and pancreas cancer. Soon after its 
discovery, studies also revealed its expression in acute leukemia, pertaining to 
worse prognosis. These views are considered out of date, since the gene's 
expression is not necessarily related to shorter survival. However, the 
assessment of WT1 expression is a useful tool in the monitoring of minimal 
residual disease. There is little knoen data on the presence of WT1 gene 
expression in malignant lymphomas due to a lack of sufficient trials. 
Broadening our knowledge about WT1 could help improve the assessment for 
prognosis, follow-up and treatment of adult and childhood leukemia. 
 
Overview 
 
The WT1 gene 
 
After the discovery of Wilms tumor, the WT1 gene was described as a 
tumor suppressor gene, although later its role as an oncogene also became 
obvious. Its dual role depends on the co-factors present, the functions of 
related genes, cell types and the degree of differentiation. 
WT1 is often expressed in several tissue types throughout the 
embryonal development. It is essential for kidney growth, since a disturbance 
in its expression leads to developmental abnormalities, even Wilms tumor. It 
partakes in gonadal sex differentiation, helps regulate the proliferation of 
cardiomyocytes, it is also present in the development of coronary arteries and 
the mesothelium which constitutes the pleura and the peritoneum. It has an 
important role in liver development, additionally, heavy WT1 expression was 
observed in skeletal muscle, brain and spinal ependymal tissue at embryonic 
age. 
In healthy adults, few organs and tissues express WT1. About 1% 
expression rate was observed in adult kidney podocytes, gonadal Sertoli and 
granulosa cells, mesothelial cells and cells of the bone marrow – the 
hemopoietic stem cells. 
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Although WT1 was discovered first in Wilms tumor, its role in the 
evolution of other solid tumors was also confirmed in the past decade. It has 
shown increased expression in mesothelial carcinoma, rhabdomyosarcoma, 
breast cancer, colorectal carcinoma, pancreas carcinoma and non-small cell 
lung cancer. An early discovery was its increased expression in hematological 
malignancies such as AML, ALL, and MDS. There is little known data about 
WT1’s relation to lymphomas. Expression has been observed in lymph nodes 
affected by Hodgkin’s lymphoma, Burkitt’s Lymphoma, DLBCL and ALCL 
(anaplastic large cell lymphoma), the prognostic value of this phenomenon has 
not yet been assessed. 
 
 
Acute Myeloid Leukemia 
 
In cases of acute myeloid leukemia (AML), the ratio of myeloblasts in 
the bone marrow is equal to or above 20%. Assessment of chromosome 
abnormalities are crucial for proper evaluation of patients’ prognosis. Aside 
from that, patient age, clinical condition, primary or secondary disease, 
response to induction and the depth of remission achieved, along with the 
presence of specific markers or lack thereof play an important part in it. The 
optimal treatment for adult acute myeloid leukemia has not yet been made 
clear. There is obvious difference between younger (<60 years of age) and 
older patients concerning treatment, since older patients require dose reduction 
depending on their biological state, furthermore, treatment could shift into 
palliative and supportive care. Chemotherapeutic treatment for AML patients 
may be divided into induction and consolidation phases. Treatment success 
can be measured by evaluating remission completion, depth, disease-free 
survival and overall survival. Rescue protocols have been used to deal with 
recurrence. In case of recurrence, stem cell transplantation should be the goal 
kept in mind. There are numerous promising new drugs being studied that 
might aid patients with resistance or recurrence. 
 
 
Diffuse Large B-Cell Lymphoma 
 
Diffuse large B-cell lymphoma (DLBCL) is the most common adult 
lymphoid malignancy. Diagnosis is based on lymph node biopsy and the Ann 
Arbor system is used for staging. The choice for treatment also depends on 
patient risk assessment with IPI (International Prognostic Index). Aside from 
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the usual prognostic markers, cases with poor therapeutic reaction can be 
detected using interim PET-CT. Survival for non-disseminated disease is 
between 80-85%, for disseminated disease however, the rate is around 50%. 
The treatment for DLBCL usually implies intensive chemotherapy (such as 
RCHOP). After the achievement of CR by agressive chemotherapy, 
autologous stem cell transplantation is recommended in case of recurrence or 
an individually bad prognosis. The treatment arsenal for DLBCL has also 
grown in the last few years. 
 
 
Goals 
 
Working in cooperation with the Department of Human Genetics, this 
study seeks to answer the following 
1. Can WT1 expression be assessed from peripheral blood samples, 
using our method? 
2. Can a quantifyable range for pathological WT1 expression be 
established? 
3. What is the prognostic value of WT1 expression evaluation in AML at 
the time of diagnosis and after the first induction therapy? 
4. Can WT1 expression trials be used for monitoring MRD in AML? 
5. Can WT1 expression be measured reliably using peripheral blood in 
DLBCL? 
6. Does WT1 expression have any prognostic value in DLBCL? 
 
 
Materials and Methods 
 
60 AML patients and 25 DLBCL patients were included between 
October 2006 and October 2014. 
The peripheral blood samples were analyzed in the Department of 
Human genetics, University of Debrecen. Samples were collected into 
PAXgene Blood RNA Tubes for mRNA isolation. RNA isolation was 
performed using PAXgene Blood RNA Kit. Real Time qRT-PCR was used 
for detecting WT1 gene expression (Applied Biosystems 7500), evaluation 
was presented by TaqMan reaction (Applied Biosystems Hs00240913-ml 
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Assay). To quantify WT1 expression, a reference gene was needed that shows 
constant and high levels of expression, we applied the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene. Instead of using the ’Ct’ cycle 
threshold for the calculations, we decided to use the amplification rate of a 
DNA solution of known concentration for both genes. We applied the Ct 
values on a calibration curve, allowing the evaluation of the mRNA 
concentration in the samples. A standardized numerical value (arbitrary unit) 
was set up, namely the number of WT1 mRNA molecules per 104 GAPDH 
mRNA molecules. For further calculation, we used the aforementioned values. 
To mark WT1 expression as positive, a cut-off value had to be 
determined. A control group of 35 of healthy volunteers of different age and 
sex was introduced. The WT1 expression measurements from blood samples 
were normalized to GAPDH expression levels, ranging between 0.002-0.109. 
All control peripheral blood samples expressed WT1 to some degree. The data 
gathered has shown a normal distribution which we fitted on a χ2 function 
(p=0.9923). When using a normal distribution variable, the upper 2.5 
percentage is usually considered significant, therefore we rounded up the 97.5 
percentile value (0.108) and set the WT1 positivity threshold to 0.1. Since the 
WT1 expression varied greatly among patients (0.0077-239.0), another 
threshold value had to be added for high WT1 expression levels (10.0). 
Categorizing patients as either WT1 positive or WT1 negative became 
possible using these threshold values. 
 
 
Results 
 
WT1 expression in AML patients 
 
WT1 expression at the time of diagnosis 
 
53 out of 60 patients (88.33%) showed WT1 positivity at the time of 
discovery. No statistic correlation was shown between the level of WT1 
expression at the time of diagnosis with neither the white blood cell count, 
medullary blast ratio, the primary or secondary nature of the disease, patient 
age and cytogenetic alterations. 
All seven non-expressing patients showed better survival than the 52 
WT1 positive patients, the difference however was insignificant (p=0.0812). 
22 out of the 53 positive WT1 cases (41%) achieved complete 
remission with induction treatment. Three of the 7 (43%) initially WT1 
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negative patients achieved CR so the disease-free survival (remission time) 
could only be assessed in these cases. The difference in overall survival was 
also insignificant (p=0.1232). 
Similar results were observed when comparing the initially WT1 
negative and WT1 positive patients' overall survival (41 cases of de novo 
AML) (p=0.134). WT1 positive patients’ overall survival seemed better, yet 
the difference was not significant. 
 
Changes in WT1 expression after the first induction treatment 
 
Another set of WT1 expression tests were conducted after the first 
chemotherapeutic treatment in 49 cases. All 49 patients underwent induction 
therapy. Aside from the 7 initially WT1 negative cases, another additional 11 
patients became WT1 negative, making up a total of 18 sub-threshold WT1 
values and 31 supra-threshold values. 
The overall survival of the now 18 WT1 negative patients and the 31 
WT1 expressing patients showed significant differences (p<0.0001). The WT1 
negative patients estimated 2-year survival was 61%, with a median survival 
of 206 weeks, while the WT1 positive patients 2-year survival estimate was 
24%, with a median survival of 46 weeks. 
There was also a significant difference in disease-free survival 
(p=0.018) between the 14 WT1 negative and 11 WT1 positive patients who 
achieved CR. 
 
Changes in WT1 expression and the survival of the three patient 
groups after induction treatment 
 
After the induction therapy, the surviving patients were divided into 
three groups to better evaluate the difference in survival related to WT1 
negativity. The first group involved 7 subjects who were WT1 negative both 
before and after induction treatment, only 3 of them were in complete 
remission, therefore they were the only ones available for determining DFS. 
The second group involved patients who were WT1 positive all along. This 
included 31 subjects, 11 of which achieved CR, DFS calculation thus became 
available. The third group included patients who were initially WT1 positive 
and became WT1 negative after induction treatment. WT1 expression levels 
were below threshold in 11 patients in total, all of them achieved CR. 
OS was significantly different among the three groups (p=0.0015). 
The best OS result (median survival 222 weeks, 50-324 weeks) was seen with 
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those 11 patients who initially expressed WT1 and became WT1 negative 
after induction, in such case, the 2-year survival vas 63%. OS was somewhat 
worse (median 180 weeks, 34-324 weeks) with patients who did not express 
WT1 at all (7 patients), their 2-year survival rate was 57%. The worst OS 
(median 43 weeks, 5-209 weeks) was seen with patients expressing WT1 all 
along, these 31 patients had a 2-year survival rate of a mere 7,8%. 
Significant difference was seen in disease-free survival as well 
(p=0.0471). Disease-free survival was 100% in the WT1 negative group, since 
all three patients achieved CR stayed in remission (median 167 weeks, 71-167 
weeks). The initially WT1 positive and later WT1 negative patients' (11 
patients) DFS was 65% at two years (median 192 weeks, 27-282 weeks). The 
worst two-year DFS (27%) was seen in the only WT1 positive group (median 
73 weeks, 7-205 weeks) 
 
Therapeutic results after the first induction and during follow-up, 
divided by patient groups 
 
• After the first chemotherapeutic treatment, the 25 (51%) out of the 49 
patients achieved CR. The remission rate among all 60 patients was 
42%. 
• Out of the 7 patients all along being WT1 negative, 3 patients 
achieved CR and 4 patients developed PR (42% and 58%, 
respectively). The three CR patients remained alive even after follow-
up and kept their remission. The 4 PR patients did not survive by the 
end of follow-up. 
• Concerning the 31 patients expressing WT1 during the entire study, 
11 patients (35%) achieved CR after the first induction, 10 (32%) 
patients developed PR and 10 patients (32%) showed resistance. The 
11 CR patients' WT1 expression levels did not reach sub-threshold. 
By the end of the follow-up, only 4 out of these 11 CR patients 
survived, 2 out of 4 (25%) were still in remission. None of the other 
20 patients survived. 
• The initially WT1 expressing then WT1 negative group of 11 patients 
showed CR in all cases. 7 patients survived by the end of the follow-
up, 6 of which were still in CR. 
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• By the end of the follow-up, 11 out of the 14 surviving patients were 
in CR. 3 patients (27%) belonged in the completely WT1 negative 
group, with a median survival of 136 weeks. Six patients (55%) 
belonged in the initially WT1 expressing then WT1 negative group, 
median survival was 247.5 weeks, and 2 patients (18%) belonged in 
the steadily WT1 positive group, their survival was 209 weeks and 
156 weeks. The three non-CR patients were still being treated due to 
their active state of disease. 
• In general terms, patients who showed WT1 positivity during the 
entire study had the worst survival rates and CR values, only 2 out of 
the 11 patients who achieved remission managed to stay in remission 
by the end of the follow-up. The remission rate was lower in patients 
who had WT1 negativity during the entire study when compared to 
those who developed WT1 negativity during this period, not many of 
them could achieve remission (42%), although those who did 
remained so for the rest of the follow-up. In contrast, the patients who 
acquired WT1 negativity during the study achieved a 100% CR, yet 
45% of the patients showed recurrence and 36% of them eventually 
died by the end of the follow-up. 
• Upon examination of the patients who later became WT1 negative, we 
have decided that four non-APL and three APL patients should be 
mentioned in detail. One of them relapsed after the second induction, 
two patients relapsed during consolidation and one patient relapsed 
after chemotherapy. All four relapses expressed WT1 positivity, none 
of the WT1 negative patients relapsed. All three APL patients 
achieved CR. 
 
WT1 gene expression levels 
 
We wished to evaluate whether the amount of WT1 expression affects 
prognosis. To do so, we have divided the 53 initially WT1 positive patients 
into two groups based on WT1 expression levels. 19 patients were put in the 
first group with their WT1 expression levels varying between 0.1 and 9.99, 
they were determined as slightly positive, while the highly positive group 
included 34 patients (expression level above 10.0). No significant difference 
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was observed in overall survival (p=0.5286). 8 slightly positive and 14 highly 
positive patients achieved CR, their DFS curves did not differ significantly 
(p=0.4719). 
We observed no difference when observing those 31 patients who 
remained WT1 positive after treatment. We compered the overall survival 
between 14 slightly and 17 highly expressing patients (p=0.6773). No 
significant difference was seen in DFS, either (11 patients in total: 2 slightly 
WT1 positive, 9 highly WT1 positive) (p=0.401). 
There was no significant difference in OS (p=0.3112) even when 
comparing the overall survival among those 11 patients who became WT1 
negative after first induction treatment (5 slightly WT1 positive, 6 highly 
WT1 positive patients). The results were similar with all 11 patients when 
comparing DFS (p=0.3674). 
Observing those 31 patients whose WT1 positivity was above cut-off 
value even after the first induction treatment, it appears a singe logarithmic 
decrease in expression by value (7 patients) does not affect overall survival, 
when compared to those patients whose WT1 expression levels did not 
decrease by a logarithmic value (24 patients) (p=0.9228). There was no 
significant difference in DFS, either (p=0.2254). Similarly, decrease in WT1 
expression by 2 logarithmic values had no influence on overall survival 
(p=0.5186) or disease-free survival (p=0.0648) in patients who remained WT1 
positive after the first induction treatment (3 patients expressed decreased 
values, 4 did not). In broad terms, instead of the decrease in expression, the 
WT1 negativity (i.e. achievement of sub-threshold level expression) 
developing after treatment proves to be the determining factor for 
improvement in OS and DFS. 
 
 
WT1 expression in DLBCL 
 
No correlation was found between initial WT1 positivity and the 
disease’s other features such as clinical stage, IPI score and the presence of B 
symptoms. 
OS and DFS results of WT1 positive and WT1 negative patients were 
compared. The 17, initially WT1 negative patients’ overall survival (median 
131 weeks; range 5-141 weeks) was significantly better (p=0.0475) than the 8 
WT1 positive patients’ (median 103 weeks; range 40-224 weeks). The WT1 
negative patients’ 2-year survival probability was 68.8%, while the WT1 
positive group achieved only 37.5%. 
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After treatment, 17 (68%) of all DLBCL patients achieved CR, 6 
achieved PR and two patients showed resistance. In terms of WT1 expression 
levels, 5 out of 8 (63%) WT1 positive patients achieved CR, two (25%) 
achieved PR and one (12%) developed resistance. 12 out of the 17 (70%) 
WT1 negative patients achieved CR, 4 (24%) achieved PR and one (6%) 
remained resistant to treatment. Among the 14 patients who died during the 
study, 7 belonged in the WT1 positive group and 7 belonged in the WT1 
negative group. 
There was a significant difference in disease-free survival related to 
WT1 expression (p=0.0004). The remission’s duration among WT1 positive 
patients were shorter (median 22 weeks; range 11-204 weeks) than WT1 
negative patients (median 113 weeks; range 66-152 weeks). 
Aside from assessing the initial WT1 values, post-treatment changes 
were also measured. We have separated the steadily WT1 negative patients, 
the initially non-WT1 expressive then WT1 positive patients, and the 2 
patients who developed WT1 expression later, and compared the overall 
survival rates. Although the small number of patients does not allow us to 
establish solid conclusions, we could say that those who became WT1 positive 
during the study period and those who were WT1 positive all along had 
significantly poorer survival rates than WT1 negative patients (p=0.006), 
therefore this phenomenon could predict especially bad prognosis. 
There was a crucial difference between those who achieved remission 
if we compare the three group’s DFS periods. Patients who were WT1 
negative during treatment showed significantly better survival than entirely 
WT1 positive patients or those who became WT1 positive during the study 
period (p=0.0002). 
 
 
Discussion 
 
The relationship between Wilms tumor gene and AML 
 
The gene’s oncogenic function was proven merely two years after its 
discovery, in contrast to this, its role in the development of leukemia remains 
uncertain. Previously, it was believed that high WT1 expression levels at the 
time of discovery meant poor prognosis. The latest data are controversial as 
the initially WT1 negative patients’ prognosis was not significantly different. 
Our results were coherent to these findings. Our studies suggest that the 
presence of gene expression after chemotherapy correlates with worse DFS 
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and OS. We believe the WT1 gene expression’s value lies in MRD 
assessment. WT1 positivity post-treatment indicates MRD positivity and a 
higher chance for relapse. 
 
Wilms tumor gene expression in AML patients 
 
There is a rich literary background on WT1 assessment from bone 
marrow samples in leukemia patients, still there is little data supporting 
peripheral blood samples as an adequate source for gene expression studies, 
even though there is less ‘background noise’ from the 1-2% percent of 
pluripotent stem cells that physiologically express this gene and the sample 
can be taken non-invasively from both patient and healthy control groups. We 
analyzed peripheral blood samples, which is rarer in this scenario. We have 
done concurrent bone marrow and peripheral blood analysis initially; the 
results were in accord with data found in literature. It should be noted that we 
have detected (sub-threshold) WT1 expression in healthy volunteers as well, 
this was in accordance with the literary finding which states about 30-40% 
healthy people’s peripheral blood samples may express WT1 activity. 
 
Determining gene expression levels 
 
Logarithmic decrease (or change) in WT1 mRNA levels relating to 
patients’ response to therapy was used in studies available in literature. Our 
study was the first to use GAPDH gene as a reference for normalization to 
determine WT1 expression threshold. Based on the WT1 expression found in 
healthy volunteers, we set the WT1 positivity threshold to 0.1. This number 
has no denomination and we used it to quantify WT1 expression, using this 
threshold allowed us to mark patients as either WT1 negative or WT1 
positive. Since patients’ observed WT1 expression levels varied on a large 
scale, a second threshold value had to be added to separate strongly positive, 
high rate of WT1 expression (10.0). 
 
Clinical Features of Leukemia 
 
We confirmed WT1 expression in 88.33% of leukemia patients at the 
time of discovery. This rate is in accordance with literary results. There was 
no correlation between the presence and rate of WT1 expression and the FAB 
subtype, medullary blast invasion, initial peripheral cell count, karyotype, 
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FLT3 positivity or NPM1 negativity. Similar results were observed in 
international studies involving larger patient groups. 
 
WT1 Expression at the Time of Diagnosis 
 
The 2-year survival, overall survival and disease-free survival were all 
more favorable in WT1 negative cases when compared to WT1 positive cases, 
however this was not statistically significant. Therefore, we did not find any 
prognostic value of higher WT1 expression levels at AML’s discovery, this is 
consistent with findings in the literature. 
 
 
Changes in WT1 expression after induction treatment 
 
All patients entered CR who initially showed WT1 positivity and then 
achieved sub-threshold WT1 expression levels. Those who were WT1 
negative at the time of discovery or achieved this later had significantly better 
OS and DFS. 
To assess the importance of WT1 negativity after the first induction 
treatment, we divided our patients into three groups. Aside from a group 
containing WT1 positive patients since discovery and a group of WT1 
negative patients since discovery, we also included a group that initially was 
WT1 positive but then became WT1 negative after treatment. According to 
our data, the initially WT1 expressing then WT1 negative group achieved 
significantly better OS. 
The three groups responded to induction therapy in different ways. 
42% of the entirely WT1 negative group achieved CR and kept it (DFS 
100%). In contrast, all the initially WT1 positive then WT1 negative patients 
achieved CR after first induction therapy, but 45% of them relapsed. The 
entirely WT1 positive patients’ response to therapy and time of remission was 
the most unfavorable. 
Our results were in accordance with the model that proposes WT1 
gene’s dual role in leukemogenesis, stating that in case of WT1 negativity 
achieved by chemotherapy (if there is lasting remission) WT1’s oncogenic 
effect is supposedly eliminated and its tumor suppressor activity may reach 
normal values. Based on the observation that even patients with sub-threshold 
WT1 levels may respond poorly to treatment (not achieving CR) it is possible 
that there is a loss off tumor suppressor function which is not always corrected 
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by the induction treatment. Patients expressing the supposedly all along active 
(i.e. oncogenic) WT1 gene responded poorly at best. 
Several studies claim that high WT1 values in patients achieving CR 
is unfavorable, suggesting that increased WT1 levels after induction treatment 
may be of prognostic value. Our results could support this, since those who 
were all along WT1 positive (WT1 expression above the 0.1 threshold) had 
unfavorable results. 
Decrease in one or two logarithmic values in WT1 expression showed 
no prognostic value concerning survival if WT1 expression levels were in the 
pathologic range, i.e. sub-threshold value, as our data suggests. 
Out of the 11 patients who became WT1 negative after the first 
induction treatment, 4 patients WT1 expression values rose above the 
threshold. According to previous studies an increase in WT1 expression may 
predict clinical relapse by weeks. The lack of WT1 level elevation in our APL 
patient helped us exclude recurrence. 
Our work also supports that the determination and follow-up of WT1 
gene expression may be an effective tool to observe MRD in patients with 
acute leukemia. This is in accordance with other, international research 
committee’s results. An increase in gene expression could be an early sign of 
relapse. 
 
 
Relations between WT1 Gene and DLBCL 
 
One of the first questions during our work was sampling method. 
Evaluation of WT1 gene expression by immunohistochemistry from 
histological samples is well known, however, subsequent sampling could be 
difficult. In our study, we tried to determine whether WT1 gene expression 
can be safely assessed by qRT-PCR from peripheral blood samples. While 
writing this essay, we encountered no data in the literature explaining 
increased WT1 expression in the peripheral blood of patients with NHL. 
Presumably, the increase in number of WT1 expressing pathological cells 
could be an explanation to the issue. 
 
WT1 Expression in DLBCL Patients 
 
32% of the patients were found WT1 positive. Despite the small 
number of patients, the rate of WT1 positivity is in accordance with the data 
from studies that used lymph node biopsy in NHL. The similar results in WT1 
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expression level with different sampling methods lead to suggest that it may 
not necessary to measure WT1 expression from lymph node biopsy for 
follow-up, peripheral blood sampling may suffice. 
WT1 expression levels did not correlate with initial tumor mass, 
clinical stage, patient age, IPI score or the presence of B symptoms. 
There was however, a significant difference in overall survival 
between WT1 expressing and non-expressing patients.  Presumably, a greater 
number of malignant cells enter the bloodstream in WT1 positivity, suggesting 
a more aggressive disease which comes with poor prognosis. 
Disease-free survival of WT1 negative patients achieving CR was 
proven to be better than with patients who initially achieved CR but remained 
WT1 positive. Although a larger number of WT1 positive patients achieved 
CR, the time of remission (and overall survival) was considerably shorter, the 
leading cause of death being lymphoma progression. This might suggest that a 
more intensive induction treatment, an early autologous stem cell transplant or 
a treatment targeting a different area of effect is required with initially WT1 
positive patients. 
Two, initially WT1 negative patients showed WT1 expression during 
treatment, their disease made quick progression and they soon relapsed. 
Naturally, we cannot make any conclusions from merely two cases but their 
remarkably bad survival calls for further evaluation, since standard 
immunochemotherapeutic treatment obviously needs addition or revision in 
such cases. 
 
In general, our data suggests that WT1 gene may also have a role in 
the pathogenesis of DLBCL, aside from acute leukemia, which may be related 
to the oncogenic function of WT1. Our results point out that determining WT1 
gene expression may be useful in elucidating a better prognosis, monitoring 
treatment and in the early prediction of relapse in DLBCL patients, this may 
change therapeutic approach. If consecutive MRD tests show disease 
progression, even initial WT1 positivity may suggest the need to intensify the 
treatment which may very well be stem cell transplant during first CR. In a 
wider scope, it might become an immunotherapeutic tool. Studies with greater 
number of patients are required for further exploration. 
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New findings and considerations 
 
1. We were first to measure WT1 expression threshold from peripheral 
blood and healthy controls, using GAPDH as an endogenous reference 
gene, results were proven pathological above said threshold. WT1 
positivity begins above 0.1, the threshold for strong WT1 positivity 
was set at 10.0 
2. We were first to prove in a Hungarian patient population that the 
initially WT1 negative group’s survival seemed more favorable, yet 
the difference was not statistically significant 
3. We found that AML patients who became WT1 negative due to 
treatment (i.e. achievement of molecular remission) showed 
significantly better survival when compared to the altogether WT1 
positive and altogether WT1 negative patients 
4. The rate of therapeutic response was lower in constantly WT1 
negative AML patients, however, after having achieved CR, no 
recurrence was seen 
5. Decrease in supra-threshold WT1 expression by 1 log value or 2 log 
values did not affect survival in AML patients 
6. We were first to measure WT1 expression from peripheral blood 
samples in DLBCL. We observed the same occurrencerates than in 
lymph node biopsy as the literary background suggests 
7. The initial increase in WT1 expression in DLBCL did not correlate to 
any characteristic parameters used for prognosis (age, clinical stage, 
IPI score, B symptoms) 
8. DLBCL patients’ overall survival and disease-free survival was 
proven to be significantly better if they did not show WT1 expression 
9. As with AML, pathological increase in WT1 during treatment may 
suggest relapse in patients with DLBCL, therefore the evaluation of 
WT1 expression is a useful tool for establishing MRD and for disease 
monitoring 
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